Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 June;53(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 June;53(3):336-342

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEW  TREATMENT OF HCC AND LIVER METASTASES BY MEANS OF RADIONUCLIDE THERAPY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 June;53(3):336-342

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases

Dierckx R. 1,4, Maes A. 2, Peeters M. 3, Van De Wiele C. 4

1 Department of Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands
2 Department of Nuclear MedicineKortrijk AZ Groeninge and Catholic University Leuven Leuven, Belgium
3 Division of Hepatogastroenterology Department of Internal Medicine Ghent University Hospital, Ghent, Belgium
4 Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium


FULL TEXT  


Local ablative therapies and loco-regional therapies are being increasingly used for the purpose of providing local control of primary liver tumors and liver metastases while sparing normal liver tissue. In this manuscript, literature on the use of fluorodeoxyglucose positron emission tomography (FDG PET) to monitor local and loco-regional treatment for hepatocellular carcinoma (HCC) and liver metastases, mainly limited to radiofrequency ablation (RFA) and selective internal radiation therapy (SIRT) is reviewed. Available data obtained primarily in secondary liver tumors and to a lesser extent in HCC support the notion that FDG PET performed early after RFA provides additional information about the efficacy of local tumor ablation by differentiating post-treatment changes from residual or recurrent malignant tumor. In addition, FDG PET was shown to have an added value for the detection of tumor recurrence. Thus, FDG PET imaging may not only improve treatment evaluation but also provide an opportunity for early re-intervention following RFA. Potential problems that might occur when using FDG PET for the purpose of evaluation of RFA are false negative results due to partial volume effect when dealing with small lesions (<1 cm) or due to diabetes and false positive results due to abscess formation. Larger studies are warranted to confirm these promising results. With regard to SIRT, several studies, almost exclusively performed in patients suffering from liver metastases, have addressed the feasibility of using FDG PET for the assessment and quantification of metabolic response of SIRT with 90Y-microspheres. These studies consistently show that traditional morphological imaging, computed tomography/magnetic resonance imaging, is insensitive in monitoring response, owing to the presence of necrosis, edema, hemorrhage and cystic changes, when compared to metabolic imaging. Thus, in view of the lack of reliability of tumor markers and/or the potential for delineating the presence of extra-hepatic metastatic cancers in these patients, when confirmed by additional studies, FDG PET may prove to be an excellent adjunct for assessing response following SIRT of liver metastases.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail